



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	313702	Manganese Plus
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Interclinical Laboratories Pty Ltd	
<b>Postal Address</b>	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	29/01/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . Manganese Plus**

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	29/01/2019
---------------------	-------------------------	-----------------------	------------

**Permitted Indications**

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support collagen formation
- Maintain/support heat/energy production/thermogenesis
- Maintain/support general health and wellbeing
- Maintain/support connective tissue health
- Aid/assist/helps connective tissue production/formation
- Maintain/support bone health
- Aids/assists healthy bone development/growth/building
- Maintain/support heart health
- Maintain/support muscle function
- Aid/assist/helps glucose/sugar/carbohydrate metabolism
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Maintain/support nerve conduction
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support nervous system function

**Indication Requirements**

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.  
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

No Warnings included on Record

#### Additional Product information

#### Pack Size/Poison information

##### Pack Size

##### Poison Schedule

#### Components

##### 1 . Formulation 1

**Dosage Form** Capsule, hard  
**Route of Administration** Oral

#### Visual Identification

#### Active Ingredients

<b>manganese (II) glycinate</b>	<b>55.43 mg</b>
Equivalent: manganese	15 mg
<b>thiamine nitrate</b>	<b>1.23 mg</b>
Equivalent: thiamine	1 mg

#### Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate  
citric acid  
colloidal anhydrous silica  
hypromellose  
magnesium stearate  
microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary